Vaxcyte Inc (PCVX) is trading up at $66.23 (+4.00%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Analyst price targets on PCVX
One firm's current price target on Vaxcyte Inc: $89 — 34% above the current $66.2. Each is tracked to its date and scored the same way a member's call is.
- BTIG $73.8 → $89 by Oct 2027 Oct 5, 2026 via Investing.com · BTIG's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Vaxcyte Inc net income history (FY2018–FY2025)
| FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$35.5M | −$54.2M | −$89.6M | −$103.7M | −$232.3M | −$468.0M | −$569.5M | −$923.7M |
| Net income | −$29.5M | −$50.3M | −$89.2M | −$100.1M | −$223.5M | −$402.3M | −$463.9M | −$766.6M |
| EPS (diluted) | −$8.12 | −$13.25 | −$3.02 | −$1.93 | −$3.44 | −$4.14 | −$3.80 | −$5.63 |
| Balance sheet | ||||||||
| Cash and equivalents | $66.1M | $59.0M | $386.2M | $69.0M | $834.7M | $397.5M | $387.9M | $174.0M |
| Total assets | — | $65.7M | $392.8M | $324.3M | $1.01B | $1.41B | $3.51B | $3.00B |
| Total liabilities | — | $11.8M | $47.0M | $40.3M | $52.6M | $167.4M | $205.5M | $317.2M |
| Shareholders' equity | −$57.7M | −$106.4M | $345.8M | $284.0M | $953.6M | $1.24B | $3.31B | $2.69B |
| Cash flow | ||||||||
| Operating cash flow | −$30.5M | −$47.1M | −$46.6M | −$121.4M | −$170.6M | −$296.8M | −$452.6M | −$655.6M |
| Capital expenditure | $1.77M | $1.20M | $1.16M | $6.55M | $5.84M | $16.1M | $22.4M | $13.7M |
| Free cash flow | −$32.2M | −$48.3M | −$47.8M | −$127.9M | −$176.4M | −$312.9M | −$475.1M | −$669.3M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$139.9M | −$162.2M | −$180.8M | −$226.2M | −$242.4M | −$274.3M | −$345.9M | −$302.8M |
| Net income | −$103.1M | −$137.1M | −$140.7M | −$166.6M | −$212.8M | −$246.5M | −$320.6M | −$284.3M |
| EPS (diluted) | −$0.83 | −$1.02 | −$1.04 | −$1.22 | −$1.56 | −$1.81 | −$2.30 | −$1.97 |
| Balance sheet | ||||||||
| Cash and equivalents | $1.05B | $387.9M | $346.9M | $306.7M | $281.1M | $174.0M | $260.8M | $183.2M |
| Total assets | $3.56B | $3.51B | $3.38B | $3.31B | $3.17B | $3.00B | $3.35B | $3.14B |
| Total liabilities | $142.1M | $205.5M | $178.1M | $234.0M | $278.7M | $317.2M | $352.3M | $380.2M |
| Shareholders' equity | $3.42B | $3.31B | $3.20B | $3.07B | $2.89B | $2.69B | $3.00B | $2.76B |
| Cash flow | ||||||||
| Operating cash flow | −$60.7M | −$111.4M | −$166.3M | −$121.2M | −$143.3M | −$224.8M | −$280.6M | −$232.5M |
| Capital expenditure | $4.95M | $4.02M | $5.42M | $1.81M | $3.82M | $2.65M | $2.11M | $4.32M |
| Free cash flow | −$65.7M | −$115.4M | −$171.7M | −$123.0M | −$147.1M | −$227.5M | −$282.7M | −$236.8M |
From Vaxcyte Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Vaxcyte Inc
- Headquarters
- San Carlos, California From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International